Genmab's HuMax-CD4 Designated as Orphan Drug by FDA

Strategic Insights -

HuMax-CD4, a high-affinity human antibody developed by Genmab, A/S, has been designated as an orphan drug by the U.S. Food and Drug Administration (FDA) for the treatment of Mycosis Fungoides (MF), a type of cutaneous T-cell lymphoma (CTCL) affecting approximately 16,000-20,000 individuals in the United States. This designation, granted under the Orphan Drug Act, provides Genmab with access to protocol assistance to maximize the chance of success at the time of marketing authorization. With HuMax-CD4 now having orphan drug status in both the United States and Europe, Genmab is poised to revolutionize the treatment of CTCL.

Key Takeaways:

  • HuMax-CD4 has been designated as an orphan drug by the FDA for the treatment of Mycosis Fungoides (MF), a type of cutaneous T-cell lymphoma (CTCL) affecting approximately 16,000-20,000 individuals in the United States.
  • The Orphan Drug Act provides companies with access to protocol assistance to maximize the chance of success at the time of marketing authorization for seven years after FDA approval.
  • HuMax-CD4 has shown positive results in two phase II studies, one for early-stage patients and the other for patients with advanced disease.
  • Genmab has gained orphan drug status for HuMax-CD4 in both the United States and Europe, highlighting the potential for this treatment to become a new standard for CTCL.
  • Lisa N. Drakeman, PhD, CEO of Genmab, emphasized the significance of HuMax-CD4's orphan drug designation, stating, "This designation highlights the importance of HuMax-CD4 as a potential new treatment for CTCL."

Statistics:

  • 16,000-20,000: estimated U.S. prevalence of Mycosis Fungoides (MF) (Source: unknown)
  • 7 years: market exclusivity granted to orphan drugs after FDA approval (Source: U.S. Food and Drug Administration)
  • 2: number of phase II studies conducted by Genmab using HuMax-CD4 to treat CTCL (Source: Genmab, A/S)
  • 2004: year Genmab announced HuMax-CD4's orphan drug designation by the FDA (Source: NewsRx.com & NewsRx.net)

Sources:

  • NewsRx.com & NewsRx.net: "Genmab, A/S, announced HuMax-CD4 for the treatment of Mycosis Fungoides (MF)"
  • Genmab, A/S: "HuMax-CD4: A high-affinity human antibody for the treatment of life-threatening and debilitating diseases"
  • U.S. Food and Drug Administration: "Orphan Drug Act"